Jiangsu Hengrui Pharmaceut-h (1276.HK) traded up 0.67 % during a 24 hours period ending at 03:18 PM Central Europe on Monday 26th. One Jiangsu Hengrui Pharmaceut-h stock can currently be bought for about HKD 47.14 on popular exchanges. Current supply of Jiangsu Hengrui Pharmaceut-h stocks is 7.6 bn. Jiangsu Hengrui Pharmaceut-h has a current market capitalization of HKD 364 bn and approximately HKD 204.2 mn worth of Jiangsu Hengrui Pharmaceut-h was traded on exchanges in the last 24 hours. Since last month end, Jiangsu Hengrui Pharmaceut-h has traded 4.92 % up. Simple moving average of last 200 days is at HKD 59.9. The highest price of past 52 weeks was recorded at HKD 80.95 on 01/14/2026. 52 weeks low was at HKD 43.02 on 09/14/2026.
Summary of the latest news for Jiangsu Hengrui Pharmaceut-h
Jiāngsū Hēngrùi Yīpǐn, a listed pharmaceutical company in China, has recently reported financial results that highlight a shift in industry focus toward performance and value creation. According to a market‑wide report released during the 11th Innovation Drug & Investment Conference, the Chinese biopharmaceutical sector has moved from a pipeline‑centric narrative to a greater emphasis on commercial outcomes and earnings delivery. The company’s disclosures reflect this trend, with management noting the importance of aligning research and development efforts with clear market potential and regulatory pathways. Investors have observed that while overall sector market value has declined, the number of listed firms has increased, indicating a maturing landscape that rewards firms capable of demonstrating tangible progress. The company’s recent filings also underscore its commitment to adopting advanced tools, including artificial intelligence, to accelerate development and improve valuation transparency.
Here is how related stocks have performed in the past 24 hours:
Yum China (9987.HK) traded up 3.08 % and now trades at HKD 352.4. Current market capitalisation for Yum China is HKD 358.9 bn. Yum China has a current price to earnings ratio of 15.89. YUM CHINA Holdings Inc. announced a share‑buyback program that included purchases on both the Hong Kong and New York exchanges. The company repurchased 24,000 Hong Kong‑listed shares at a price near HKD340 to HKD347, and 60,500 ADRs on the New York Stock Exchange at a price close to USD44.40 to USD44.75. The repurchase effort, approved by the company’s board, brings the total shares repurchased to roughly 9.48 million, representing a small but notable fraction of the issued shares. This activity reflects YUM CHINA’s ongoing strategy to manage capital and support its stock in a stable market environment.
Eoptolink L (300502.SZ) traded flat 0 % and now trades at CNY 252.35. Eoptolink L has a market capitalisation of CNY 363.9 bn. Eoptolink L has a current price to earnings ratio of 27.81. EOPTOLINK TECHNOLOGY INC L experienced a decline in its share price on October 26, 2026, as part of a broader pullback in optical‑module stocks. The company’s shares fell in the low‑single‑digit percentage range, contributing to the downward pressure seen across the sector. The move coincided with a general market swing that left several technology names, including other optical‑module providers, in a selling phase, while other sectors such as consumer staples and real estate showed relative resilience. No significant corporate announcements or earnings updates were linked to the price movement. The decline reflects the sector‑wide adjustment rather than a company‑specific event.
Citic (0267.HK) traded up 0.93 % and now trades at HKD 11.94. Citic has a market capitalisation of HKD 346.8 bn. Current price/earnings ratio for Citic is 4.85.
Wuliangye Yibin (000858.SZ) traded flat 0 % and now trades at CNY 75.63. Wuliangye Yibin has a market capitalisation of CNY 286.7 bn. Current price/earnings ratio for Wuliangye Yibin is 132.92. Financial analysts noted that WULIANGYE YIBIN CO LTD, a leading producer of high‑grade baijiu, has recently reported modest performance in its third‑quarter earnings. The company’s revenues are projected to show a slight decline, consistent with broader industry trends driven by reduced sales during the national holiday period. While overall sales volume has contracted, the firm is expected to maintain its focus on high‑margin product lines, which may help offset the downward pressure on volume. Market observers anticipate that, as the industry shifts toward a more balanced supply–demand environment, companies with stronger brand positioning and efficient cost management—such as WULIANGYE YIBIN—are likely to gradually improve their earnings relative to peers. The forthcoming earnings release will be closely watched for indications of how the company adapts its pricing and distribution strategy in response to the current market slowdown.
China Telecom -Dm (0728.HK) traded down -1.15 % and now trades at HKD 4.34. China Telecom -Dm has a market capitalisation of HKD 394.9 bn. Current price/earnings ratio for China Telecom -Dm is 10.94.
About Jiangsu Hengrui Pharmaceut-h
Jiangsu Hengrui Pharmaceuticals Co Ltd is a health care company based in Lianyungang, China. The company specializes in developing, manufacturing, and marketing a variety of medicines and medicine packaging materials. Their product range includes anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and other related products. You can find more information about the company and their offerings on their website at www.hrs.com.cn . The company is listed on the Shanghai Stock Exchange. Their initial public offering (IPO) date was September 7, 2000.
